title: Lubiprostone: a new drug for the treatment of chronic idiopathic constipation.
abstract: Lubiprostone offers an additional alternative for patients with chronic idiopathic constipation. Lubiprostone is more efficacious than placebo in the treatment of chronic idiopathic constipation. In placebo-controlled clinical trials, lubiprostone therapy was generally well tolerated and was not associated with severe adverse effects; however, the high incidence of nausea may be problematic for some patients. The nausea may be alleviated or minimized by administering the dose with food, and some patients may require a dosage reduction to 24 mug once daily. The key limitations of the placebo-controlled clinical trials include the absence of information regarding the duration of the constipation and previous types of therapies that had been used to treat the constipation and the absence of an active control group. Comparative studies with other therapies (eg, saline laxatives, polyethylene glycol) used for constipation are necessary to determine the clinical and economic value of this agent relative to other forms of therapy.
authors.affiliation: College of Pharmacy, Washington State University Spokane, Spokane, Washington, USA.
authors.forename: Danial E
authors.initials: DE
authors.lastname: Baker
mesh_terms: D000527:Alprostadil / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D018118:Chloride Channels / Q000187:drug effects; D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation / Q000379:methods*; D005227:Fatty Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D000068238:Lubiprostone; D016896:Treatment Outcome
chemical_list: D018118:Chloride Channels; D005227:Fatty Acids; D000068238:Lubiprostone; D000527:Alprostadil